Contribute Try STAT+ Today

Many Canadian medical societies and specially focused disease groups fail to disclose industry funding in their clinical practice guidelines, a new analysis finds. Moreover, most of the organizations included conflict-of-interest statements in their guidelines, but also had a panel member with a conflict.

Of 21 organizations that issued practice guidelines between 2016 and 2018, three reported they did not receive industry funding and all were sponsored by the Canadian government. In addition, none of their guidelines committee members disclosed a financial conflict of interest, according to the analysis in CMAJ, a journal published by the Canadian Medical Association.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hey Ed,

    Does Canada have anything similar yo the US Sunshine Act? Just curious. It’s the easiest and quickest way to assess financial tie between a drug company and any physician, regardless of whether he or she is a member of the editorial board or guideline drafting group.

Comments are closed.